GoPath Diagnostics Launches DiabetesNow for Better Diabetes Diagnosis
GoPath Diagnostics has introduced DiabetesNow, a groundbreaking genetic test panel designed to enhance the clarity of diabetes diagnoses for patients. This innovative tool combines an extensive analysis of 16 genes associated with various monogenic forms of diabetes, including MODY and other variants. It also assesses polygenic risk scores for type 1 and type 2 diabetes, accommodating diverse ancestries.
A Comprehensive Genetic Perspective
DiabetesNow stands out by integrating genetic testing with vital models like GenProb-T1D, which estimates the likelihood of developing type 1 diabetes based on genetic and clinical information. This multifaceted approach not only aids in discerning complex cases but also helps identify critical SNPs correlated with both type 1 and type 2 diabetes.
Facilitating Early Detection and Intervention
One of the major benefits of DiabetesNow is its ability to clarify ambiguous diagnoses. By identifying inherited gene variants that family members might share, the test promotes early detection for those relatives at risk. Such proactive measures are crucial when distinguishing MODY from more traditional diabetes types, ensuring patients receive the most appropriate therapy.
Targeting Unique Cases for Tailored Solutions
Designed especially for patients presenting atypical symptoms or diagnosed at a younger age, DiabetesNow addresses specific needs like those regarding mild or non-progressive hyperglycemia. The selection of the 16 genes included in the panel was guided by both the Monogenic Diabetes Expert Panel (MDEP) and current clinical guidelines, ensuring relevance and efficacy.
Dr. Jim Lu's Insight and Vision
Dr. Jim Lu, CEO and Medical Director of GoPath Diagnostics, emphasizes the utility of DiabetesNow: "This panel brings together crucial genetic markers, enabling healthcare providers to better differentiate between various diabetes presentations and deliver more personalized treatment options.”
Robust Data Backing Clinical Practice
With a solid foundation supported by an internal database of previously tested patients, GoPath provides clinically actionable insights through thorough variant interpretation. Each DiabetesNow test report offers detailed monogenic variant analyses, PRS percentile ranks by ancestry, and a calculated GenProb-T1D score, all in one comprehensive document.
Aligning with Current Clinical Standards
Reflecting the most recent breakthroughs in diabetes genetics, DiabetesNow adheres to the latest research, including findings published in reputable journals. The test is structured to align with the upcoming American Diabetes Association (ADA) Standards of Care, ensuring it remains at the cutting edge of diabetes care.
About GoPath Diagnostics
Founded with the mission to enhance patient care, GoPath Diagnostics specializes in several areas, including molecular and genetic pathology. Their commitment to utilizing advanced technologies and having a dedicated team of professionals enables the provision of precise and timely diagnostic results. For more information about their services, visit GoPath Diagnostics.
Frequently Asked Questions
What is DiabetesNow?
DiabetesNow is a genetic test panel that combines testing for 16 genes related to diabetes and polygenic risk scores for better diagnosis and treatment.
Who can benefit from DiabetesNow?
This panel is particularly beneficial for patients diagnosed with diabetes at a young age, or those presenting atypical symptoms that do not align with standard diabetes types.
How does DiabetesNow aid in distinguishing diabetes types?
It identifies inherited gene variants and assesses polygenic risks, helping healthcare providers clarify uncertain diagnoses like distinguishing MODY from type 1 or type 2 diabetes.
What kind of results can one expect from the DiabetesNow test?
Test reports include comprehensive insights such as monogenic variant analysis, ancestry-based PRS, and a GenProb-T1D score.
How does GoPath Diagnostics ensure the effectiveness of DiabetesNow?
GoPath leverages data from previously tested patients and aligns the panel's offerings with the latest clinical guidelines and research to ensure accurate results.
